Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.

Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, Kufrin D, Palmby T, Dong Z, Russell AM, Miksinski S, Keegan P, Pazdur R.

Clin Cancer Res. 2013 May 1;19(9):2289-93. doi: 10.1158/1078-0432.CCR-12-1956. Epub 2013 Mar 20.

2.

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.

Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ.

J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1.

3.

Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.

Proctor AE, Thompson LA, O'Bryant CL.

Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. Review.

PMID:
24259609
4.

Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.

Cirrone F, Harris CS.

Clin Ther. 2012 Oct;34(10):2039-50. doi: 10.1016/j.clinthera.2012.08.011. Epub 2012 Oct 1. Review.

PMID:
23036338
5.

Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.

Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J.

JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780. Review.

PMID:
27096888
6.

Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.

Dessinioti C, Plaka M, Stratigos AJ.

Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.

PMID:
24941979
7.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A.

N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713.

8.

Vismodegib (Erivedge) for basal cell carcinoma.

[No authors listed]

Med Lett Drugs Ther. 2012 Jul 9;54(1394):53-4. No abstract available.

PMID:
22777303
9.

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J.

Lancet Oncol. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. Epub 2015 May 13.

PMID:
25981813
10.

Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns.

[No authors listed]

Prescrire Int. 2015 Jan;24(156):11-4.

PMID:
25729822
11.

Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.

Lyseng-Williamson KA, Keating GM.

Am J Clin Dermatol. 2013 Feb;14(1):61-4. doi: 10.1007/s40257-012-0004-6.

PMID:
23329081
12.

Vismodegib for periocular and orbital basal cell carcinoma.

Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ.

JAMA Ophthalmol. 2013 Dec;131(12):1591-4. doi: 10.1001/jamaophthalmol.2013.5018.

PMID:
24136169
13.

Vismodegib granted FDA approval for treatment of basal cell carcinoma.

[No authors listed]

Oncology (Williston Park). 2012 Feb;26(2):174, 213. No abstract available.

14.

Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.

Sobanko JF, Okman J, Miller C.

J Drugs Dermatol. 2013 Oct;12(10 Suppl):s154-5. Review.

PMID:
24085062
15.

Vismodegib in the treatment of advanced BCC.

O'Kane GM, Lyons T, McDonald I, Mulligan N, Moloney FJ, Murray D, Kelly CM.

Ir Med J. 2014 Jul-Aug;107(7):215-6.

PMID:
25226719
16.

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A; ERIVANCE BCC investigators.

J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. doi: 10.1016/j.jaad.2015.03.021.

PMID:
25981002
17.

A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.

Erdem GU, Sendur MA, Ozdemir NY, Yazıcı O, Zengin N.

Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17. Review.

PMID:
25690490
18.

Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma.

Lyons TG, O'Kane GM, Kelly CM.

Expert Opin Drug Saf. 2014 Aug;13(8):1125-32. doi: 10.1517/14740338.2014.939952. Review.

PMID:
25033383
20.

An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.

Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, Oro A, Kim J, Chang AL, Tang JY.

J Am Acad Dermatol. 2014 Nov;71(5):904-911.e1. doi: 10.1016/j.jaad.2014.05.020. Epub 2014 Jun 11.

PMID:
24929884

Supplemental Content

Support Center